Hovione’s product portfolio is comprised of known Active Pharmaceutical Ingredients (APIs) which have been formulated to meet patient needs by increasing safety, improving compliance or expanding access by following the FDA 505(b)2 regulatory pathway. We focus on the fields of dermatology, ophthalmology and respiratory and target new routes of administration, expansion of indications and improved delivery. Hovione develops its products through Phase 1/2 and seeks partners for completion of the clinical development, regulatory approval, and commercialization.